enGene Holdings Announces Key Executive Appointments
Company Announcements

enGene Holdings Announces Key Executive Appointments

enGene Holdings ( (ENGN) ) has issued an update.

enGene Holdings Inc. has announced significant changes to its executive team on October 21, 2024, appointing Joan Connolly as Chief Technology Officer and Anthony Cheung as Chief Scientific Officer. These leadership changes aim to bolster the company’s strategic direction as it advances its lead genetic medicine, detalimogene, which is in a pivotal study for treating high-risk bladder cancer. With Connolly’s extensive experience in regulatory and commercialization aspects, enGene is poised to enhance its operational capabilities in driving its clinical assets to market.

Learn more about ENGN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyenGene files to sell 46.98M common shares, 6.29M warrants for holders
TheFlyenGene files $300M mixed securities shelf
TipRanks Auto-Generated NewsdeskenGene Holdings Secures $60 Million for Genetic Medicines
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App